Pharmafile Logo
Pharmafocus logo
Advanced Search

selumetinib

Showing 4 posts of 4 posts found.

astrazeneca_building_white

AstraZeneca’s selumetinib fails to meet primary endpoint in lung cancer trial again

August 9, 2016
Manufacturing and Production AstraZeneca, failure, non-small cell lung cancer, phase III, selumetinib, trial failure

AstraZeneca has announced that its MEK 1/2 inhibitor, selumetinib, failed to meet its primary endpoint of progression free survival in …

News
Astrazeneca image

AstraZeneca bags another FDA orphan status in cancer

April 17, 2015
Sales and Marketing AstraZeneca, Cancer, FDA, GlaxoSmithKline, mekinist, melanoma, oncology, selumetinib, trametinib

The FDA has granted AstraZeneca’s cancer medicine selumetinib orphan drug designation for the treatment of uveal melanoma. The company will …

News
AstraZeneca imge

AZ begins late-stage trial of new cancer drug

October 22, 2013
Research and Development, Sales and Marketing AstraZeneca, Cancer, NSCLC, selumetinib

AstraZeneca has begun a Phase III study for its investigational lung cancer pill selumetinib in patients with a genetic sub-type …

News

Trial disappointment for AZ lung cancer drug

October 3, 2011
Research and Development, Sales and Marketing AstraZeneca, selumetinib

AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025